Transfer of porcine endogenous retrovirus across hollow fiber membranes: Significance to a bioartificial liver

Transplantation

Volumn 67, Issue 9, 1999, Pages 1251-1255

  Nyberg, Scott L ^a   Hibbs, Jonathan R ^a   Hardin, Joseph A ^a   Germer, Jeffery J ^a   Persing, David H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; ARTIFICIAL LIVER; MEMBRANE PERMEABILITY; MEMBRANE STRUCTURE; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS INHIBITION; VIRUS TRANSMISSION;

ANIMALS; ARTIFICIAL ORGANS; CELL LINE; CELLULOSE; DNA, VIRAL; ENDOGENOUS RETROVIRUSES; HUMANS; KIDNEY; MEMBRANES, ARTIFICIAL; POLYMERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONES; SWINE;

EID: 0033562516     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199905150-00009     Document Type: Article

References (23)

1. Patience C, Takeuchi Y, Weiss R. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3: 282.
2. Wilson C, Wong S, Muller J, Davidson C, Rose T, Burd P. Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. J Virol 1998; 72: 3082.
3. Todaro G, Benveniste R, Lieber M, Sherr C. Characterization of a type C virus released from the porcine cell line PK(15). Virology 1974; 58: 65.
4. Le Tissier C, Staye J, Takeuchi Y, Patience O, Weiss R. Two sets of human-tropic pig retrovirus. Nature 1997; 389: 681.
5. Bach F, Fishman J, Daniels N, et al. Uncertainty in xenotransplantation: individual benefit versus collective risk. Nat Med 1998; 4: 141.
6. Sachs D, Colvin R, Cosimi A, Russell P, Sykes M. Xenotransplantation-caution, but no moratorium [Letter]. Nat Med 1998; 4: 372.
7. Demetriou AA, Rozga J, Podesta L, et al. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol Suppl 1995; 208: 111.
8. Watanabe F, Mullon CJ-P, Hewitt W, et al. Clinical experience with a bioartifical liver (BAL) in the treatment of severe liver failure: a phase I clinical trial. Ann Surg 1997; 225: 484.
9. Lazar A, Peshwa M, Wu F, Chi C-M, Cerra F, Hu W-S. Formation of porcine hepatocyte spheroids for use in a bioartificial liver. Cell Transplantation 1995; 4: 259.
10. Hewitt W, Chen S, Watanabe W, et al. Treatment of acute hepatic failure with porcine hepatocyte-based bioartificial liver (BAL). Hepatology 1996; 24: 436A.
11. Chen S, Hewitt W, Watanabe F, et al. Clinical experience with a porcine hepatocyte-based liver support system. Int J Artif Organs 1996; 19: 664.
12. Sheil AG, Sun J, Mears DC, et al. Preclinical trial of a bioartificial liver support system in a porcine fulminant hepatic failure model. Aust N Z J Surg 1996; 66(8): 547.
13. Sielaff T, Nyberg S, Rollins M, et al. Characterization of the three compartment gel entrapment porcine hepatocyte bioartificial liver. Cell Biol Toxicol 1997; 13: 357.
14. Lieber M, Sherr C, Benveniste R, Todaro G. Biologic and immunologic properties of porcine type C viruses. Virology 1975; 66: 616.
15. Martin U, Kiessig V, Blusch J, et al. Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet 1998; 352: 692.
16. Fishman JA. Miniature swine as organ donors for man: strategies for prevention of xenotransplant-associated infections. Xenotransplantation 1994; 1: 47.
17. Chapman LE, Folks TM, Salomon DR, Patterson AP, Eggerman TE, Noguchi PD. Xenotransplantation and xenogeneic infections. N Engl J Med 1995; 333(22): 1498.
18. Weiss R. Viruses in pig organs could infect humans: Discovery complicates transplant prospects. Washington Post. Washington, DC, 1997: A8.
19. Weiss R. Retroviral zoonoses. Nat Med 1998; 4: 391.
20. Armstrong J, Porterfield J, De Madrid A. C-type virus particles in pig kidney cell lines. J Gen Virol 1971; 10: 195.
21. Peltekian K, Levy G. Role of cytokines and immune mechanisms in acute liver failure. In: Lee WM, Williams R, eds. Acute liver failure. Cambridge, United Kingdom: Cambridge University Press, 1997: 67.
22. Paradis K. Potential transmission of porcine endogenous retrovirus to humans. The Transplantation Society 98 Book of Abstracts 1998: 291.
23. Watanabe F, Kahaku E, Ting P, et al. Absence of porcine endogenous retrovirus (PERV) infection after treatment with a porcine-based bioartificial liver (BAL). Hepatology 1998; 28: 495A.